Molecular Profiles expands manufacturing capabilities

Molecular Profiles announces the expansion of its service offering to include new manufacturing capabilities, enabling the company to handle larger projects for pharmaceutical clients from preformulation through to Phase IIa. This new manufacturing capability will initially focus on the company's expert area of difficult-to-formulate molecules and enable it to offer a greater range of services to its customers. Molecular Profiles will be discussing its manufacturing  capabilities at Informex 2011, taking place February 7-10, 2011 in Charlotte, North Carolina, USA.

Molecular Profiles has provided specialised analytical and formulation services to major pharmaceutical companies for over a decade. The new manufacturing facilities have been built within the existing site at Nottingham, UK, and with this latest service addition, Molecular Profiles now provides a complete range of services including formulation development, preformulation, polymorph screening, salt selection, analytical services and clinical trial manufacturing up to phase IIa . This decreases the need to perform a technical transfer of work to other companies and therefore lessens the risk to the customer's research.

Nikin Patel, PhD MRPharmS, CEO of Molecular Profiles, commented: "What makes Molecular Profiles unique is that we have an innovative problem-to-solution approach, which has resolved some of the toughest drug substance and formulation issues. We have a large number of highly experienced PhDs with a track record including over 1000 projects and many blockbuster products. This, coupled with our dedication to providing the best service for our customers, means we provide a consummate and cost-effective project delivery. "

Nikin continued: "The Informex exhibition will enable us to highlight our new ability to provide a comprehensive value-added pharmaceutical development service. Our company has the expertise to work on difficult-to-handle molecules and in particular, poorly water soluble drugs and highly potents. The expansion of our service offering greatly reduces the need for technical transfer and ensures products get developed in time."

For more information, visit

Recent Issues